A quick look at ZGNX suggests that they may be using an AXON type busineess model here. Would be interesting to look at their management, but can't take the time here.
Rett syndrome and Dravet syndrome (the one Zogenix reported on today) are 2 completely different disorders but both are both rare genetic disorders....The fact that Zogenix went up 172% today because they reported top line phase 3 results on their study to treat Dravet shows me that Anavex can possibly do the same (stock gain wise) with their trial in Rett syndrome.
One interesting thing to note about Zogenix is the fact that their drug trial for Dravet is the only drug trial in their entire piepline. It's all in or bust for them and it's a home run.
News 
Market Data 
Discover 
